What's Going On With Moderna Stock Today


Moderna Inc MRNA shares are trading lower by 4.11% to $133.52 going into the close of Tuesday's session after Morgan Stanley maintained an Equal-Weight rating on the stock and cut its price target from $197 to $175.

What Else?

The analyst note by Morgan Stanley highlights concerns regarding Moderna's vaccine revenue guidance.

Per the Morgan Stanley note: "We believe management could lower expectations for 2023 COVID boosters as consensus' $10B est. is well above our range of signed APAs (~$2-3.8B) and our estimate of potentialguidance (~$5-10B). The 3Q call may be a good opportunity to reset MRNA ahead of Ph2/3 data catalysts on RSV, PCV and flu."

The analyst note goes on to mention how "Investors are concerned aboutmanagement's ability to bracket consensus expectations of ~$10B in COVID vaccine revenues."

See Also: Why Norwegian Cruise Line And Royal Caribbean Group Shares Are Rising During Tuesday's Session

According to data from Benzinga Pro, Moderna has a 52-week high of $376.65 and a 52-week low of $115.03.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorPrice TargetAnalyst RatingsMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!